Skip to content
Screener

Evolus EOLS Jeuveau — Total net revenues

Other product segments

Evolysse
$8.89M-8.6%
Service revenue
$734K+6.7%

Similar metrics at other companies

Coupang logo
CPNGNet other revenue — Total net revenues
$2.03B+11.4%
Coupang logo
CPNGOther revenue — Total net revenues
$261M+1.2%
Haemonetics logo
HAEPlasma — Total net revenues
$155.52M+7.2%
Sotera Health logo
SHCProduct — Total net revenues
$43.05M+16.0%
Sotera Health logo
SHCService — Total net revenues
$278.33M+8.2%
Coupang logo
CPNGNet retail sales — Total net revenues
$6.48B+6.4%

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Cash & equivalents$45.2M-26.8%
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$501.32M+31.4%
Enterprise value$620.96M+33.1%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Evolus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:56 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053468
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue:
Jeuveau®$74,456$58,968$140,477$127,042
Evolysse®8,8949,73115,6209,731
Total product revenue, net83,35068,699156,097136,773
Service revenue7346881,1241,136
Total net revenues84,08469,387157,221137,909
Less:
Cost of goods sold26,90424,06751,14445,934

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Evolus's jeuveau — total net revenues?
Evolus (EOLS) reported jeuveau — total net revenues of $74.46M in Q2 2026.
How has Evolus's jeuveau — total net revenues changed year-over-year?
Evolus's jeuveau — total net revenues increased by 26.3% year-over-year, from $58.97M to $74.46M.
What is the long-term trend for Evolus's jeuveau — total net revenues?
Over 2 years (2023 to 2025), Evolus's jeuveau — total net revenues has grown at a 16.8% compound annual growth rate (CAGR), from $199.72M to $272.32M.
What does jeuveau — total net revenues mean?
This metric represents the total net revenue generated from the sale of the company's primary botulinum toxin product within the aesthetic market. It reflects the core commercial performance and market adoption of the product after accounting for returns, allowances, and discounts. This figure serves as a key indicator of the company's ability to capture market share in the self-pay aesthetic sector.

Ask your AI about Evolus's jeuveau — total net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude